• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

光化性角化病计量学。

Actinic keratosis metrics.

机构信息

Brody School of Medicine, East Carolina University, Greenville, NC, USA.

University of California San Francisco, San Francisco, CA, USA.

出版信息

Arch Dermatol Res. 2024 Aug 20;316(8):543. doi: 10.1007/s00403-024-03305-5.

DOI:10.1007/s00403-024-03305-5
PMID:39162820
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11335770/
Abstract

Actinic keratosis (AK) is a common precancerous skin condition predominantly affecting older males with fair skin and significant UV exposure. The clinical significance of AK is related to its potential for malignant transformation and progression to squamous cell carcinoma (SCC). Accurate diagnosis of AK is essential for adequate treatment, evaluation of therapeutic efficacy, and mitigating the risk of developing SCC. However, clinician variability due to the subjective nature of current diagnostic tools presents significant challenges to achieving consistent and reliable AK diagnoses. Thus, there is no universally accepted standard for measuring AK.This review evaluates current methods for evaluating and diagnosing AK, focusing on clinician variability through inter- and intraobserver agreement. Eight peer-reviewed studies investigating the reliability of various approaches for AK evaluation show substantial variability in interobserver or intraobserver agreement, with most methods demonstrating only slight to moderate reliability. Some suggest that consensus discussions and simplified rating scales can modestly improve diagnostic reliability. However, remaining variability and the lack of a universally accepted standard for measuring AK underscore the need for more robust and standardized diagnostic and evaluation methods.The review emphasizes the need for improved diagnostic tools and standardized methods to enhance the accuracy and reliability of AK assessments. It also proposes applying a novel examination approach using 1,3-dihydroxyacetone (DHA) staining which may improve the visualization and identification of AK lesions. Advancements in these areas have significant potential, promising better clinical practices and patient outcomes in AK management.

摘要

光化性角化病(AK)是一种常见的癌前皮肤疾病,主要影响皮肤白皙且有大量紫外线暴露史的老年男性。AK 的临床意义与其恶性转化和进展为鳞状细胞癌(SCC)的潜力有关。AK 的准确诊断对于充分治疗、评估治疗效果以及降低 SCC 发生风险至关重要。然而,由于当前诊断工具的主观性,临床医生之间存在很大的差异,这对实现一致和可靠的 AK 诊断提出了重大挑战。因此,目前还没有普遍接受的 AK 测量标准。

本综述评估了目前用于评估和诊断 AK 的方法,重点关注通过观察者间和观察者内一致性来评估临床医生的差异。八项同行评议的研究调查了各种 AK 评估方法的可靠性,结果显示观察者间或观察者内的一致性存在很大差异,大多数方法仅显示出轻微到中度的可靠性。一些研究表明,共识讨论和简化的评分量表可以适度提高诊断的可靠性。然而,剩余的差异以及缺乏普遍接受的 AK 测量标准,突显了需要更强大和标准化的诊断和评估方法。

本综述强调了需要改进诊断工具和标准化方法,以提高 AK 评估的准确性和可靠性。还提出了一种使用 1,3-二羟基丙酮(DHA)染色的新型检查方法,该方法可能改善 AK 病变的可视化和识别。这些领域的进展具有很大的潜力,有望在 AK 管理方面改善临床实践和患者结局。

相似文献

1
Actinic keratosis metrics.光化性角化病计量学。
Arch Dermatol Res. 2024 Aug 20;316(8):543. doi: 10.1007/s00403-024-03305-5.
2
Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications.光化性角化病进展为鳞状细胞癌的再探讨:临床及治疗意义
Cutis. 2011 Apr;87(4):201-7.
3
Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression.患者报告的非黑素瘤皮肤癌和光化性角化病患者的健康结局:一项大规模观察性研究分析诊断和疾病进展影响的结果。
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1138-1146. doi: 10.1111/jdv.14703. Epub 2018 Jan 12.
4
Agreement on the clinical diagnosis and management of cutaneous squamous neoplasms.皮肤鳞状细胞肿瘤的临床诊断和治疗共识。
Dermatol Surg. 2010 Oct;36(10):1514-20. doi: 10.1111/j.1524-4725.2010.01675.x.
5
Progression of skin lesions from normal skin to squamous cell carcinoma.皮肤病变从正常皮肤发展为鳞状细胞癌。
Anal Quant Cytol Histol. 2009 Feb;31(1):17-25.
6
Management of actinic keratosis at specific body sites in patients at high risk of carcinoma lesions: expert consensus from the AKTeam™ of expert clinicians.特定高危皮肤癌病变部位光化性角化病的管理:AKTeamTM 专家临床医生的专家共识。
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):339-346. doi: 10.1111/jdv.14753. Epub 2018 Jan 15.
7
Significance of cyclooxygenase 2, EZH-2 polycomb group and p53 expression in actinic keratosis and squamous cell carcinomas of the skin.环氧化酶2、EZH-2多梳蛋白家族和p53在光化性角化病及皮肤鳞状细胞癌中的表达意义
Am J Dermatopathol. 2013 Jun;35(4):425-31. doi: 10.1097/DAD.0b013e318271292a.
8
Reflectance confocal microscopy: non-invasive distinction between actinic keratosis and squamous cell carcinoma.反射式共聚焦显微镜:非侵袭性鉴别光化性角化病和鳞状细胞癌。
J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1302-9. doi: 10.1111/jdv.12806. Epub 2014 Oct 30.
9
Comparison of morphologic criteria for actinic keratosis and squamous cell carcinoma using in vivo multiphoton tomography.使用体内多光子断层扫描技术比较光化性角化病和鳞状细胞癌的形态学标准
Exp Dermatol. 2016 Mar;25(3):218-22. doi: 10.1111/exd.12912. Epub 2016 Feb 10.
10
The diagnostic concordance of actinic keratosis and squamous cell carcinoma.光化性角化病与鳞状细胞癌的诊断一致性。
J Cutan Pathol. 2005 Sep;32(8):546-51. doi: 10.1111/j.0303-6987.2005.00381.x.

引用本文的文献

1
MMP-2-Potential Predictor of Epithelial-Mesenchymal Transition in Squamous Cell Carcinogenesis.基质金属蛋白酶-2——鳞状细胞癌发生过程中上皮-间质转化的潜在预测指标
Life (Basel). 2025 Jul 2;15(7):1060. doi: 10.3390/life15071060.
2
Human Papillomavirus Vaccination and Actinic Keratosis Burden: The VAXAK Randomized Clinical Trial.人乳头瘤病毒疫苗接种与光化性角化病负担:VAXAK随机临床试验
JAMA Dermatol. 2025 Mar 6. doi: 10.1001/jamadermatol.2025.0531.

本文引用的文献

1
Concordance in Distinguishing Actinic Keratosis from Squamous Cell Carcinoma in Situ on Mohs Histological Frozen Sections.在莫氏组织学冰冻切片上鉴别光化性角化病与原位鳞状细胞癌的一致性
J Drugs Dermatol. 2023 Feb 1;22(2):190-194. doi: 10.36849/JDD.7084.
2
Field Therapy for Actinic Keratosis: A Structured Review of the Literature on Efficacy, Cost, and Adherence.光化性角化病的局部治疗:关于疗效、成本和依从性的文献结构化综述
Dermatol Surg. 2023 Feb 1;49(2):124-129. doi: 10.1097/DSS.0000000000003677. Epub 2023 Jan 13.
3
Treatment of actinic keratosis: a systematic review.光化性角化病的治疗:系统评价。
Arch Dermatol Res. 2023 Jul;315(5):1099-1108. doi: 10.1007/s00403-022-02490-5. Epub 2022 Dec 1.
4
Inter- and Intra-physician variation in quantifying actinic keratosis skin photodamage.医生之间和医生内部在量化光化性角化病皮肤光损伤方面的差异。
J Clin Investig Dermatol. 2020 Sep;8(2). Epub 2020 Sep 6.
5
Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.光化性角化病和皮肤鳞状细胞癌。
Dtsch Arztebl Int. 2019 Sep 13;116(37):616-626. doi: 10.3238/arztebl.2019.0616.
6
Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects.光化性角化病:临床、皮肤镜及治疗方面的综述
An Bras Dermatol. 2019 Nov-Dec;94(6):637-657. doi: 10.1016/j.abd.2019.10.004. Epub 2019 Nov 6.
7
Intraclass correlation - A discussion and demonstration of basic features.组内相关系数 - 基本特征的讨论与演示。
PLoS One. 2019 Jul 22;14(7):e0219854. doi: 10.1371/journal.pone.0219854. eCollection 2019.
8
Randomized Trial of Four Treatment Approaches for Actinic Keratosis.随机对照临床试验:四种光化性角化病治疗方法的比较
N Engl J Med. 2019 Mar 7;380(10):935-946. doi: 10.1056/NEJMoa1811850.
9
Actinic Keratosis Area Severity Index (AKASI): reproducibility study and comparison with total lesion count.光化性角化病面积严重程度指数(AKASI):再现性研究及与总病损数的比较
Br J Dermatol. 2018 Sep;179(3):763-764. doi: 10.1111/bjd.16559. Epub 2018 Jun 20.
10
Dihydroxyacetone: An Updated Insight into an Important Bioproduct.二羟基丙酮:对一种重要生物制品的最新见解。
ChemistryOpen. 2018 Mar 6;7(3):233-236. doi: 10.1002/open.201700201. eCollection 2018 Mar.